Home World News FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle... World News FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 828 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Talking With Your Doctor About Negative Emotions During Cancer November 3, 2020 Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side... October 4, 2021 Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence April 29, 2019 Coping With the Difficult Times of Cancer Survivorship Through My “Bucket... August 1, 2023 Load more HOT NEWS What if we count all that still remains? Foodie Fridays-Gazpacho: A Favorite Summer Soup Discovering the BRCA2 gene – 25 years on Consensus on Conceptual Framework for Precision Cancer Medicine in Germany